Navigation Links
Omthera Pharmaceuticals Announces Positive Long Term Bioavailability Data Comparing Epanova™ to Lovaza®
Date:1/9/2012

PRINCETON, N.J., Jan. 9, 2012 /PRNewswire/ -- Omthera Pharmaceuticals, Inc., a privately held specialty pharmaceuticals company, today announced positive data from a pharmacokinetic study comparing 2 week bioavailability of Epanova to Lovaza®.  In the 52 subject clinical study, after 14 days of dosing on a low fat diet, plasma EPA and DHA levels were 5.8 fold higher in subjects dosed with Epanova compared to those dosed with Lovaza.  Additionally, Epanova increased steady state plasma levels of EPA plus DHA by 448%, compared to 90% for Lovaza.

Commenting on the results, Dr. Michael Davidson, Co-Founder and Chief Medical Officer of Omthera, stated, "We are extremely pleased with these results which confirm the superior bioavailability of Epanova over the leading prescription Omega-3 in the steady state. There is a clear dose response for triglyceride lowering with Omega-3 fatty acids and this data further supports our view that Epanova may well become the new best in class prescription product for addressing the rapidly growing unmet clinical need for the management of hypertriglyceridemia."

John J. P. Kastelein, M.D., Ph.D., Professor of Medicine and Chairman of the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, and a member of Omthera's Scientific Advisory Board, noted, "Hypertriglyceridemia and its associated increase in cardiovascular risk has become an epidemic across the world. Prescription Omega-3's, due to their safety and proven efficacy, are ideally suited to provide the clinical solution to this growing problem. The new Epanova data showing marked improvement in long term bioavailability of EPA and DHA is stunning, and enhances my opinion that this will translate into improved triglyceride lowering effects."

President and CEO, Jerry Wisler, will provide an overview of these results during Omthera's corporate presentation at
'/>"/>

SOURCE Omthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Omthera Pharmaceuticals, Inc. to Present at the 30th Annual J.P. Morgan Healthcare Conference
2. Omthera Pharmaceuticals, Inc. to Present at the 23rd Annual Piper Jaffray Health Care Conference
3. Timothy J. Maines Joins Omthera Pharmaceuticals as Vice President of Quality
4. Omthera Pharmaceuticals, Inc. to Present at the Rodman and Renshaw 13th Annual Healthcare Conference
5. Omthera Pharmaceuticals, Inc. Initiates Phase III ESPRIT Trial of Add-on Epanova™ to Statin Therapy in Patients with Hypertriglyceridemia
6. Christian S. Schade to Join Omthera Pharmaceuticals as Executive Vice President and Chief Financial Officer
7. Drs. Ben Machielse Joins Omthera Pharmaceuticals, Inc. as Chief Operating Officer
8. Omthera Pharmaceuticals, Inc. to Present at the 2011 Wells Fargo Securities Healthcare Conference
9. Omthera Pharmaceuticals, Inc. to Present at the BIO Windhover/Pharmaceutical Strategic Outlook 2011 Conference
10. Omthera Pharmaceuticals Raises $33.9 Million in Series B Funding Led by New Enterprise Associates
11. Omthera Pharmaceuticals, Inc. to Present at the 29th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... Using publicly released 2015 rate filings in ... five common specialty drugs. Specialty drugs have been ... costs and shortage of generic alternatives. They treat ... and are used for a broad variety of ... HealthPocket found that among 2015 Obamacare ...
(Date:8/26/2014)... ALISO VIEJO, Calif. , Aug. 26, 2014 ... ) today announced the enrollment of the first ... the efficacy, safety and tolerability of AVP-786 for ... AVP-786 is a novel investigational drug consisting of ... dose quinidine. "There are millions of ...
(Date:8/26/2014)... Calif. , Aug. 26, 2014  Based on its ... Sullivan recognizes Volpara Solutions with the 2014 North American Frost ... an innovative range of volumetric breast imaging solutions for the ... the company has steadily introduced several new solutions and has ... States , Europe , ...
Breaking Medicine Technology:2015 Platinum Plans Are Best Buy for Consumers Using Expensive Specialty Drugs 2Avanir Pharmaceuticals Announces Initiation of Phase II Study of AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 2Avanir Pharmaceuticals Announces Initiation of Phase II Study of AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 3Avanir Pharmaceuticals Announces Initiation of Phase II Study of AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 4Avanir Pharmaceuticals Announces Initiation of Phase II Study of AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 5Avanir Pharmaceuticals Announces Initiation of Phase II Study of AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 6Frost & Sullivan Applauds Volpara Solutions' Clear Vision in Identifying the Importance of Dose Tracking and Quantitative Analytics in the Early Detection of Breast Cancer 2Frost & Sullivan Applauds Volpara Solutions' Clear Vision in Identifying the Importance of Dose Tracking and Quantitative Analytics in the Early Detection of Breast Cancer 3Frost & Sullivan Applauds Volpara Solutions' Clear Vision in Identifying the Importance of Dose Tracking and Quantitative Analytics in the Early Detection of Breast Cancer 4Frost & Sullivan Applauds Volpara Solutions' Clear Vision in Identifying the Importance of Dose Tracking and Quantitative Analytics in the Early Detection of Breast Cancer 5
... 12, 2011 Breast Imaging facilities looking ... benefit from the exceptional image quality of the Aspire™ ... Medical Systems U.S.A., Inc. Now FDA 510(k) cleared, the ... of potential abnormalities that not only assists in more ...
... 2011 Henry Schein, Inc., (NASDAQ: ... services to office-based practitioners, announced today that Steven ... will present at the Morgan Stanley Global Healthcare Conference.  The ... City.   Henry Schein,s presentation is scheduled to ...
Cached Medicine Technology:Fujifilm's Aspire HD Receives FDA Clearance 2Fujifilm's Aspire HD Receives FDA Clearance 3Henry Schein to Present at the Morgan Stanley Global Healthcare Conference 2
(Date:8/27/2014)... D.C. (PRWEB) August 27, 2014 A ... Neurosurgery discusses the importance of time in correcting coagulopathy ... focuses on a variety of anticoagulants and examines medical ... According to the research, although anticoagulants have been approved ... and systemic embolism, they are also known to affect ...
(Date:8/27/2014)... President Obama is considering Executive action ... White House initiative that supplies green cards and work ... also open a pathway to Social Security benefits, warns ... to work authorization would add new long-term liabilities to ... the target of proposals to cut the growth in ...
(Date:8/27/2014)... PCOS (Polycystic Ovarian Syndrome) affects an estimated ... for a number of health disorders and medical conditions. ... even within the medical community. Many women are suffering ... excess body fat around the waist area (truncal obesity), ... caused by PCOS. , Awareness is the first step ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 ... PartnerTech AB, a major systems integration and electronics ... Cryotherapy offering the first U.S. designed and ... offered the ideal combination of manufacturing expertise, location, ... system. Impact Cryotherapy, headquartered in Atlanta, GA, offers ...
(Date:8/27/2014)... *Anyone who is interested in learning more about the clinical ... on the web ( http://www.availclinical.com ) or contact them directly at ... by fibromyalgia – a condition characterized by a broad range ... pain , Joint stiffness , Muscle ... Depression , Anxiety , While no ...
Breaking Medicine News(10 mins):Health News:Flood Law Group Comments on Recent AAICH Study 2Health News:The Senior Citizens League (TSCL) Warns: White House Action On Immigration Could Give Social Security To Known Illegals 2Health News:Houston 5k Supports Women With PCOS, Sponsored by Amerejuve MedSpa 2Health News:Houston 5k Supports Women With PCOS, Sponsored by Amerejuve MedSpa 3Health News:Houston 5k Supports Women With PCOS, Sponsored by Amerejuve MedSpa 4Health News:Houston 5k Supports Women With PCOS, Sponsored by Amerejuve MedSpa 5Health News:PartnerTech Inc. and Impact Cryotherapy Announce Made in America Manufacturing Initiative 2Health News:PartnerTech Inc. and Impact Cryotherapy Announce Made in America Manufacturing Initiative 3Health News:Avail Clinical Research is Looking for Qualified Individuals Who Are Interested in Participating in a Fibromyalgia Clinical Trial Near Orlando, Florida 2Health News:Avail Clinical Research is Looking for Qualified Individuals Who Are Interested in Participating in a Fibromyalgia Clinical Trial Near Orlando, Florida 3
... NEW YORK, March 11 In this 90 minute episode, ... out what happened,after they left treatment. Drew reveals who has ... The audience, which is comprised of,recovering addicts and fans of ... questions about what happened over the season., ...
... - Novadaq(R) Technologies Inc.,(TSX: NDQ), a developer of ... the operating room, today announced that Dr. Arun,Menawat, ... corporate story,technology and highlights, including an update on ... Co. Healthcare Conference. The conference,runs Monday, March 17 ...
... tumors by more than half, study found , , TUESDAY, ... the 60 percent of women with breast cancer whose malignancies ... letrozole (Femara) can cut risk of a recurrence by more ... initiated the drug one to seven years after they stopped ...
... TALLAHASSEE, Fla., March 11 Based on,overwhelming response, ... FSDDS,Florida Sun Defense Essay Contest have been extended ... Dermatology and Dermatologic Surgery,(FSDDS), the contest is designed ... about the importance of sun safety. Four overall,winners ...
... AARP Services Inc. and,Genworth Financial, Inc. (NYSE: ... a,new long term care insurance plan for AARP,s ... affordable alternative to traditional,long term care insurance and ... with more states anticipated., (Logo: http://www.newscom.com/cgi-bin/prnh/20070209/NYF043LOGO ...
... 11 Verathon(R) is pleased to,announce a new ... 9400,bladder volume instrument with patent-pending NeuralHarmonics(TM),Technology. Small Child ... noninvasively on children weighing less than 60 pounds ... same instrument used for adult,patients. This enhanced BladderScan(R) ...
Cached Medicine News:Health News:Novadaq to present at Cowen Healthcare Conference 2Health News:Late Use of Aromatase Inhibitor Still Effective Against Breast Cancer 2Health News:Late Use of Aromatase Inhibitor Still Effective Against Breast Cancer 3Health News:Deadline Extended for Essay Submissions to the FSDDS Sun Defense Essay Contest Throughout Florida Elementary Schools 2Health News:AARP Services Inc. and Genworth Financial Introduce New Innovative and Affordable Long Term Care Insurance Option to AARP Members 2Health News:AARP Services Inc. and Genworth Financial Introduce New Innovative and Affordable Long Term Care Insurance Option to AARP Members 3Health News:AARP Services Inc. and Genworth Financial Introduce New Innovative and Affordable Long Term Care Insurance Option to AARP Members 4Health News:Verathon Inc. Launches Enhanced BladderScan(R) Bladder Volume Instrument With Small Child Mode 2Health News:Verathon Inc. Launches Enhanced BladderScan(R) Bladder Volume Instrument With Small Child Mode 3
Sterile perfluorocarbon for intraocular Application....
Sterile Silicone Oil for Intraocular Application....
Alcon offers medical grade perfluoropropane (SF6) intraocular gases for ophthalmological use....
Silikon 1000 (purified polydimethylsiloxane) is a highly purified long chain polydimethylsiloxane trimethylsiloxy terminated silicone oil. For use as a postoperative retinal tamponade during vitreore...
Medicine Products: